Values as of: 2025-03-09
COMMON STOCK | Biotechnology |
Last Closing
USD 202Change
0.00 (0.00)%Market Cap
USD 39.40BVolume
N/AAnalyst Target
N/AVerdict
Verdict
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as for other immunology diseases like atopic dermatitis, ankylosing spondylitis, Crohn's disease, hidradenitis suppurativa, juvenile idiopathic arthritis, non-radiographic axial spondyloarthritis, osteoporotic fractures, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus. It also provides Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company provides Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. Further, the company's clinical development pipeline includes doxecitine for TK2 deficiency disorder; rozanolixizumab and Zilbrisq to treat myasthenia gravis, fenfluramine for the treatment of seizures associated with Lennox-Gastaut and Dravet syndrome; dapirolizumab pegol for systemic lupus erythematosus, STACCATO alprazolam for stereotypical prolonged seizures are products of phase 3; and bepranemab to treat Alzheimer's disease, UCB0222 for Parkinson's disease, and UCB9741 and UCB1381 for atropic dermatitis are products of phase 2a. Additionally, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Company Website : https://www.ucb.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ARGNF | argenx SE |
N/A |
USD 42.38B |
| UCBJY | UCB SA ADR |
N/A |
USD 39.56B |
| GNMSF | Genmab A/S |
N/A |
USD 14.30B |
| WXXWY | WuXi Biologics (Cayman) Inc |
N/A |
USD 12.58B |
| WXIBF | WuXi Biologics |
N/A |
USD 12.52B |
| AKESF | Akeso, Inc. |
N/A |
USD 8.30B |
| IVBIY | IVBIY |
N/A |
USD 7.97B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 7.81B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 7.77B |
| TLPPF | Telix Pharmaceuticals Limited |
N/A |
USD 6.05B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| EDMF:F | 2.44 % | 0.00 % |
N/A |
N/A | |
| EWK | iShares MSCI Belgium ETF | 0.00 % | 0.47 % |
N/A |
N/A |
| MEU:CA | 0.00 % | 0.61 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 2.52% | 54% | F | 50% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 2.52% | 54% | F | 50% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 70.32% | 84% | B | 89% | A- | ||
| Dividend Return | 1.23% | 42% | F | 13% | F | ||
| Total Return | 71.55% | 84% | B | 88% | B+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 107.82% | 91% | A- | 85% | B | ||
| Dividend Return | 7.35% | 70% | C- | 16% | F | ||
| Total Return | 115.17% | 91% | A- | 82% | B | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 18.46% | 60% | D- | 63% | D | ||
| Dividend Return | 19.92% | 60% | D- | 62% | D | ||
| Total Return | 1.46% | 77% | C+ | 34% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 47.20% | 68% | D+ | 53% | F | ||
| Risk Adjusted Return | 42.20% | 93% | A | 79% | B- | ||
| Market Capitalization | 39.40B | 99% | N/A | 97% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
